HIV prevention drugs known as PrEP are highly effective, but many at risk don’t know about them

Despite the availability of highly effective HIV prevention drugs such as pre-exposure prophylaxis (PrEP), a large number of individuals at risk in the U.S. are not taking advantage of them or even aware of their existence. According to the Centers for Disease Control and Prevention (CDC), PrEP is about 99% effective in preventing HIV infection through sexual contact when taken as prescribed. However, only around one-third of the estimated 1.2 million Americans who could benefit from the medication are currently using it.

One individual, LaTonia Wilkins, shared her experience of not knowing about PrEP until years after an HIV scare. She mentioned that she believed PrEP was only for gay men or trans women and was unaware that it was an option for her. This lack of awareness and misconceptions surrounding PrEP highlight the need for better education and outreach efforts.

It’s important to understand who is at risk for HIV and may benefit from PrEP. According to Dr. Céline Gounder, those considered at risk include individuals who are engaging in unprotected sex with a partner who has HIV, have multiple sexual partners who have not been tested for HIV, or have had a sexually transmitted disease (STD) in the last six months. These criteria encompass a wide range of individuals who could benefit from HIV prevention measures.

However, there are significant disparities in PrEP usage among different demographic groups. While 94% of White individuals who could benefit from PrEP are currently using it, the numbers are much lower for Black and Hispanic/Latino individuals as well as women. Dázon Dixon Diallo, who founded a women’s health advocacy group in Atlanta, emphasized the need to address these disparities and normalize conversations about sex and HIV.

One of the barriers to accessing PrEP is the cost, which includes the medication, clinic visits, and lab tests, averaging over $5,000 per year. This financial burden can make it challenging for individuals like Wilkins to afford the medication, especially if insurance coverage is limited or unavailable. Additionally, a federal court case could potentially restrict insurance coverage for PrEP, further complicating the situation for those who rely on it for HIV prevention.

In conclusion, increasing awareness, addressing disparities, and improving accessibility to PrEP are crucial steps in the fight against HIV. By providing education, reducing stigma, and ensuring affordable access to preventive measures, we can work towards a future where the spread of HIV is significantly reduced. It is essential for individuals, healthcare providers, and policymakers to collaborate in promoting HIV prevention and supporting those at risk in the community.